Back to Search
Start Over
Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update
- Source :
- Bone marrow transplantation. 51(11)
- Publication Year :
- 2016
-
Abstract
- Emerging data demonstrate promising results of related haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HCT) for the treatment of hematologic malignancies. Data about G-CSF primed PBSC as reliable source of graft with myeloablative conditioning are lacking. We updated the outcomes in 130 adult patients with high-risk hematologic malignancies who received haplo-PBSC transplantation consecutively under busulfan-based conditioning. PBSC were freshly isolated and infused without ex vivo T-cell depletion into the recipients. Myeloid recovery was achieved in 99.2% patients with full donor chimerism. The cumulative incidence of acute grade 3-4 GvHD, overall and extensive chronic GvHD was 14.9%, 38.6% and 16.5%, respectively. The 3-year non-relapse mortality rate was 24.1%. Non-remission prior to transplant was associated with higher incidence of relapse (P=0.006), inferior overall survival (P=0.017) and leukemia-free survival (P=0.024). These data suggest that PBSC is a reliable graft source in haploidentical, unmanipulated transplant settings under myeloablative conditioning in patients with high-risk hematologic malignancies.
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
Transplantation Conditioning
Adolescent
medicine.medical_treatment
Myeloablative Agonist
Graft vs Host Disease
Hematopoietic stem cell transplantation
Chimerism
Risk Assessment
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Granulocyte Colony-Stimulating Factor
medicine
Humans
Cumulative incidence
Child
Busulfan
Transplantation
Peripheral Blood Stem Cell Transplantation
business.industry
Hematology
Middle Aged
Myeloablative Agonists
medicine.disease
Survival Analysis
Granulocyte colony-stimulating factor
surgical procedures, operative
Graft-versus-host disease
Treatment Outcome
030220 oncology & carcinogenesis
Hematologic Neoplasms
Immunology
Transplantation, Haploidentical
Female
business
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 14765365
- Volume :
- 51
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Bone marrow transplantation
- Accession number :
- edsair.doi.dedup.....978a73844556fb8bbc1a90226673c0db